BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$368.42 USD
+10.23 (2.86%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$368.42 USD
+10.23 (2.86%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe
by Zacks Equity Research
Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.
Thermo Fisher's (TMO) New Buyouts Aid, Cost Pressure Ails
by Zacks Equity Research
Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.
Myriad Genetics (MYGN) Makes Progress in Precision Oncology
by Zacks Equity Research
Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.
Walgreens (WBA), Village MD Plan to Expand Into New Hampshire
by Zacks Equity Research
Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.
Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.
Here's Why You Should Hold on to Insulet (PODD) Stock For Now
by Zacks Equity Research
Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.
Here's Why You Should Hold Onto Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) progress at the Food Safety and Animal Safety segments.
Teleflex (TFX) Hurt by Urolift Cancellations, Cost Woes
by Zacks Equity Research
Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.
STERIS (STE) Strategic Buyouts Aid Growth, Margin Woe Stays
by Zacks Equity Research
STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.
Cardiovascular Systems (CSII) Finances New DCB Development
by Zacks Equity Research
Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.
Medtronic (MDT) Inks Deal to Offer Touch Surgery Enterprise
by Zacks Equity Research
Medtronic's (MDT) Touch Surgery Enterprise gives surgical teams a powerful new tool to enhance patient care by simplifying the process to capture and analyze surgical videos.
Bio-Rad (BIO) Loses 15.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Bio-Rad (BIO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why You Should Retain Charles River (CRL) Stock For Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.
Allscripts (MDRX) Up 4.5% Since Q4 Earnings: What's Driving It?
by Zacks Equity Research
Allscripts' (MDRX) stock rallies on better-than-expected fourth-quarter performance and recent alliances.
Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong
by Zacks Equity Research
Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.
Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Cooper Companies (COO) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.
Thermo Fisher (TMO) Extends Collaboration With Symphogen
by Zacks Equity Research
Thermo Fisher's (TMO) recent extension of collaboration with Symphogen is intended to support biopharmaceutical discovery and development.
Medtronic (MDT) Gains Market Share Despite COVID Headwinds
by Zacks Equity Research
In Respiratory Interventions, despite the year-over-year headwind, as ventilator sales continue to return to pre-pandemic levels, Medtronic (MDT) gains about 400 basis points of share.
Quidel (QDEL) Rallies 17.4% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Quidel (QDEL) stock rallies on better-than-expected fourth-quarter performance and strong diagnostics portfolio.
Patterson Companies (PDCO) Q3 Earnings Beat, Revenues Lag
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter 2022 results benefit from strength in the Dental and Animal Health segments.
Insulet (PODD) Product Volume Up, COVID-Led Softness Persists
by Zacks Equity Research
Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.
Henry Schein (HSIC) Expands Data Analytics to Private Practices
by Zacks Equity Research
Henry Schein's (HSIC) introduction of Jarvis Analytics for Private Practices offers practice owners a simple, powerful tool to help improve practice success through data-driven decisions.